Business Context and Reporting Period
This Form 8-K was filed by BioXcel Therapeutics, Inc. (BTAI) on September 16, 2024, with a signature date of September 20, 2024. The filing addresses regulatory notices received from The Nasdaq Stock Market, LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
This filing does not contain specific financial statements, revenue, profit, cash flow, or debt figures. However, it references the following market-based metrics triggering the notices:
- Minimum Bid Price: The closing bid price of common stock was below $1.00 per share for 30 consecutive business days.
- Market Value of Listed Securities: The minimum market value was below $35 million for 30 consecutive business days.
Material Changes and Listing Status
The Company received two distinct deficiency notices from Nasdaq:
- Bid Price Notice (Sept 16, 2024): Failure to maintain a minimum bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).
- Market Value Notice (Sept 20, 2024): Failure to maintain a minimum market value of listed securities of $35 million under Nasdaq Listing Rule 5550(b)(2).
These notices do not have an immediate effect on the listing; the stock continues to trade on The Nasdaq Capital Market under the symbol "BTAI."
Outlook, Risks, and Management Commentary
Compliance Deadlines:
- Bid Price Compliance Date: March 17, 2025 (180 calendar days). The stock must close at or above $1.00 for 10 consecutive business days prior to this date.
- Market Value Compliance Date: March 19, 2025 (180 calendar days). The market value must meet or exceed $35 million for 10 consecutive business days during the grace period.
Management Actions and Risks:
- The Company is evaluating options to regain compliance, which may include a reverse stock split.
- If compliance is not met by the deadlines, the Company may be eligible for a second 180-day period for the bid price deficiency, provided it meets other listing standards.
- Failure to cure deficiencies could result in delisting, which the Company may appeal.
- Going Concern: The filing explicitly states the Company has identified conditions raising substantial doubt about its ability to continue as a going concern.
- Other Risks: Significant indebtedness, need for additional funding, limited operating history, and significant losses.
Investor Verification Checklist
- Verify the current trading price of BTAI to assess the gap to the $1.00 minimum bid requirement.
- Confirm the current market capitalization to assess the gap to the $35 million market value requirement.
- Review the Company's most recent 10-Q or 10-K for details on cash reserves, burn rate, and debt covenants given the "substantial doubt" disclosure.
- Monitor for announcements regarding a potential reverse stock split or capital raise.
- Check for any updates on the Company's drug development pipeline, as commercialization success is critical to long-term viability.